Industries > Pharma > Generic Drugs Market Report 2024-2034

Generic Drugs Market Report 2024-2034

Forecasts by Type (Simple Generics, Specialty Generics, Biosimilars), by Prescription Type (Prescription Generics, Over-the-Counter (OTC) Generics)), by Indication (Central Nervous System (CNS), Oncology, Infectious Diseases, Cardiovascular Diseases, Gastrointestinal Diseases, Musculoskeletal Diseases, Others), by Drug Class (Antibiotics, Antihistamines, Analgesics, Antihypertensive, Antidiabetic, Antipyretic, Others), by Route of Administration (Oral, Parenteral, Topical, and Others), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

PUBLISHED: 04 March 2024
PAGES: 357
PRODUCT CODE: PHA1316
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA1316 Categories: , Tags: , , ,

The Generic Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rising Geriatric Population and Cost Affordability of Generic Drugs Projected to Boost Industry Growth

The generic drugs market is expected to be significantly driven by key factors such as the rising geriatric population and the cost affordability and effectiveness of generic medications. As the global demographic structure shifts towards an aging population, the prevalence of chronic diseases increases, necessitating long-term treatments. Generic drugs, known for their therapeutic equivalence to brand-name counterparts and cost-effectiveness, emerge as crucial solutions to meet the healthcare needs of the elderly. The affordability of generic drugs aligns with the economic constraints often faced by seniors, fostering widespread adoption. Governments and healthcare systems, recognizing the financial advantages and accessibility benefits of generic drugs, are likely to support policies and initiatives that further propel market growth. The combination of a growing elderly population seeking affordable treatments and the proven effectiveness of generic drugs positions this market to play a pivotal role in addressing healthcare challenges and ensuring broader access to essential medications.

Adverse Effects Associated with Drugs Likely to Challenge Market Growth

Adverse effects associated with drugs are anticipated to pose a substantial challenge for the generic drugs market. While generic medications aim to replicate the therapeutic effects of their brand-name counterparts, the one-size-fits-all approach may not adequately address individual variations in patient response. This lack of individualized formulations raises concerns about potential adverse reactions, as patients may experience side effects or inadequate therapeutic responses. Variability in bioavailability among generic drugs further complicates the scenario, potentially leading to variations in drug concentration levels and subsequent adverse effects. Moreover, differences in inactive ingredients between generic and brand-name drugs may impact tolerability, especially for individuals with allergies or sensitivities, creating a need for standardized formulations. The limited post-market surveillance for generic drugs compared to brand-name counterparts raises challenges in timely identification and management of adverse effects, impacting consumer confidence. Addressing these adverse effects associated with generic drugs requires enhanced regulatory measures, rigorous quality control, and a focus on individualized medicine to ensure the sustained growth and success of the generic drugs market.

What Questions Should You Ask before Buying a Market Research Report?
  • How is the generic drugs market evolving?
  • What is driving and restraining the generic drugs market?
  • How will each generic drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each generic drugs submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading generic drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of generic drugs projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the generic drugs market?
  • Where is the generic drugs market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Generic Drugs Market today, and over the next 10 years:
  • Our 357-page report provides 133 tables, 223 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them – NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Generic Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects
  • In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising generic drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report
Type
  • Simple Generics
  • Specialty Generics
  • Biosimilars
Route of Administration
  • Oral
  • Parenteral
  • Topical
  • Others
Indication
  • Central Nervous System (CNS)
  • Oncology
  • Infectious Diseases
  • Cardiovascular Diseases
  • Gastrointestinal Diseases
  • Musculoskeletal Diseases
  • Others
Drug Class
  • Antibiotics
  • Antihistamines
  • Analgesics
  • Antihypertensive
  • Antidiabetic
  • Antipyretic
  • Others
Prescription Type
  • Prescription Generics
  • Over-the-Counter (OTC) Generics
Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Others

CTA

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America
  • U.S.
  • Canada
Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
MEA
  • GCC Countries
  • South Africa
  • Rest of MEA

Generic Drugs Market Report 2024-2034
Need industry data? Please contact us today.

The report also includes profiles and for some of the leading companies in the Generic Drugs Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
  • Alkem Laboratories Ltd.
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma
  • Biocon
  • Cipla Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Endo International plc
  • Lupin
  • Novartis AG
  • Sun Pharmaceuticals Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.

Overall world revenue for Generic Drugs Market, 2024 to 2034 in terms of value the market will surpass US$450.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Generic Drugs Market, 2024 to 2034 report help you?

In summary, our 350+ page report provides you with the following knowledge:

  • Revenue forecasts to 2034 for Generic Drugs Market, 2024 to 2034, with forecasts for type, prescription type, indication, drug class, route of administration, distribution channel, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2034 for five regional and 20 key national markets – See forecasts for the Generic Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market – including company profiles for 13 of the major companies involved in the Generic Drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Generic Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Generic Drugs Market Report 2024-2034: Forecasts by Type (Simple Generics, Specialty Generics, Biosimilars), by Prescription Type (Prescription Generics, Over-the-Counter (OTC) Generics)), by Indication (Central Nervous System (CNS), Oncology, Infectious Diseases, Cardiovascular Diseases, Gastrointestinal Diseases, Musculoskeletal Diseases, Others), by Drug Class (Antibiotics, Antihistamines, Analgesics, Antihypertensive, Antidiabetic, Antipyretic, Others), by Route of Administration (Oral, Parenteral, Topical, and Others), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Generic Drugs Market Report 2024-2034

    Download sample pages

    Complete the form below to download your free sample pages for Generic Drugs Market Report 2024-2034

      Latest Pharma news

      Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

      The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

      12 April 2024

      READ

      Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

      The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

      11 April 2024

      READ

      Visiongain Publishes Female Health Tech Market Report 2024-2034

      The global Female Health Tech market was estimated to be valued at US$ 140.9 billion in 2034 and is expected to register a CAGR of 9.6% from 2024 to 2034.

      05 April 2024

      READ

      Visiongain Publishes Meningococcal Vaccines Market Report 2024-2034

      The global Meningococcal Vaccines market is projected to grow at a CAGR of 2.5% by 2034

      26 March 2024

      READ